Carl Zeiss Meditec AG

  • WKN: 531370
  • ISIN: DE0005313704
  • Land: Deutschland

Nachricht vom 08.02.2021 | 07:00

Successful start to FY 2020/21 for Carl Zeiss Meditec

DGAP-News: Carl Zeiss Meditec AG / Key word(s): Quarterly / Interim Statement/Quarter Results
08.02.2021 / 07:00
The issuer is solely responsible for the content of this announcement.

Successful start to FY 2020/21 for Carl Zeiss Meditec
 
Revenue in first three months back to prior-year level; increase in operating profit due to lower costs
 

JENA, 8 February 2021

Carl Zeiss Meditec generated revenue of €368.9m in the first three months of fiscal year 2020/21 (prior year: €369.7m), corresponding to a decline of just -0.2% (adjusted for currency effects: +2.6%) compared with the year-ago period, which had not yet been impacted by the COVID-19 pandemic. Earnings before interest and tax (EBIT) increased to €73.4m (prior year: €56.8m). The EBIT margin was 19.9% (prior year: 15.4%).

Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG: "This is a good start to the new fiscal year, particularly in light of the pandemic, which is still ongoing in many markets. Our diversified portfolio has once again proven to be robust. I am particularly pleased with the strong contributions to growth from the Asia/Pacific region and the good cost discipline within the Company, which played a major role in the development of earnings."

SBU Ophthalmic Devices records sales growth again for the first time since the beginning of the pandemic

Revenue in the Ophthalmic Devices strategic business unit (SBU) increased by 5.2% in the first three months of fiscal year 2020/21 (adjusted for currency effects: +8.2%) to €283.4m (prior year: €269.4m). Recurring revenue from consumables, implants and services made significant contributions to growth. Revenue in the SBU Microsurgery fell by -14.7% (adjusted for currency effects: -12.3%), to €85.5m (prior year: €100.3m). On a currency-adjusted basis, orders received in the SBU Microsurgery were already back to the prior year's level.

APAC[1] region returns to growth - EMEA[2] and Americas almost stable

Revenue in in the EMEA region decreased slightly by -1.8% (adjusted for currency effects: +0.1%), to €108.7m (prior year: €110.7m). The trend in the markets of Germany, France and Southern Europe was stable.

The Americas region recorded a mainly currency-related decline in revenue of -6.4% (adjusted for currency effects: -0.2%) to €102.0m (prior year: €109.0m). On a currency-adjusted basis, the USA almost matched the prior year's level.

Revenue in the APAC region increased again for the first time since the start of the crisis, amounting to €158.2m compared with €150.0m in the same period of the prior year (+5.5%; adjusted for currency effects: +6.6%). Once again, the strongest contributions to growth were generated in China and South Korea. There was only a slight decline in revenue in Japan.

Operating result increased significantly year-on-year

The operating result (earnings before interest and taxes: EBIT) increased to €73.4m in the first three months of fiscal year 2020/21 (prior year: €56.8m). Low selling and marketing expenses, in particular, contributed to this. EBIT also includes positive one-time income of €2.4m from the sale of a property. The EBIT margin increased to 19.9% (prior year: 15.4%). Adjusted for special effects, this resulted in an increase to 19.8% (prior year: 15.8%). Earnings per share rose to €0.52 (prior year: €0.43).

Carl Zeiss Meditec expects revenue and EBIT to continue to recover over the further course of fiscal year 2020/21 compared with the prior year, which had been dominated by the COVID-19 pandemic.

Revenue by strategic business unit

All figures in €m 3 months 2020/21 3 months 2019/20 Change from prior year Change from prior year (currency-adjusted)
Ophthalmic Devices 283.4 269.4 +5.2% +8.2%
Microsurgery 85.5 100.3 -14.7% -12.3%
Consolidated 368.9 369.7 -0.2% +2.6%
 

Revenue by region

All figures in €m 3 months 2020/21 3 months 2019/20 Change from prior year Change from prior year (currency-adjusted)
EMEA 108.7 110.7 -1.8% +0.1%
Americas 102.0 109.0 -6.4% -0.2%
APAC 158.2 150.0 +5.5% +6.6%
Consolidated 368.9 369.7 -0.2% +2.6%
 

Further information on our publication and the Analyst Conference Call on the results for the first three months of fiscal year 2020/21 can be found at https://www.zeiss.com/meditec-ag/investor-relations/reports-publications.html

 

Contact for investors and press

Sebastian Frericks
Director Investor Relations, Carl Zeiss Meditec AG
Phone: +49 (0)3641 220-116
Email: investors.meditec@zeiss.com

www.zeiss.de/presse

[1] Asia/Pacific
[2] Europe, Middle East, Africa



08.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Event im Fokus

How to Vergütungsbericht?

Im Zulauf auf die neue Berichtssaison adressiert das hkp/// group Tutorial die wichtigsten Neuerungen für die Kommunikation von Vorstands- und Aufsichtsratsvergütung im Vergütungsbericht.

Mittwoch, 18. August 2021, 14:00 -15:30 Uhr

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Cryptology Asset Group PLC: 120 % Kurspotenzial

GBC Research hat mit der Coverage der Cryptology Asset Group PLC (ISIN: MT0001770107) begonnen. Die Bewertung der führenden europäischen Investmentgesellschaft für Krypto-Assets und Blockchain-Unternehmen erfolgte mittels der Berechnung des Net Asset Value (NAV). Unter Berücksichtigung aller Beteiligungen ergibt sich zum 05. Juli 2021 eine GBC-Fair-NAV-Bewertung in Höhe von 1,04 Mrd. EUR. Daraus ergibt sich ein NAV je Cryptology-Aktie von 358,43 EUR. Daher empfiehlt GBC Research die Cryptology-Aktie zum Kauf und sieht ein Kurspotenzial von über 120 %.

News im Fokus

Infineon Technologies AG: POSITIVE ENTWICKLUNG VON ERGEBNIS UND FREE-CASH-FLOW. UMSATZWACHSTUM TROTZ SCHWIERIGER LIEFERSITUATION. STARKES SCHLUSSQUARTAL ERWARTET

03. August 2021, 07:30

Aktueller Webcast

HelloFresh SE

Q2 2020 Results Webcast

10. August 2021

Aktuelle Research-Studie

UniDevice AG

Original-Research: UniDevice AG (von GBC AG): Kaufen

04. August 2021